Cargando…

Hydralazine-Induced Isolated Lupus Nephritis

Background: Hydralazine has been known to cause multiple side effects, both localized and systemic. The literature includes case reports of systemic vasculitis caused by hydralazine. Case Report: A 79-year-old male with stage 3 chronic kidney disease attributable to hypertension and type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Khan, Naseer, Reichel, Ronald, Khurshid, Ayesha, Tso, Katie, Broussard, Joan, Dass, Amrika
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academic Division of Ochsner Clinic Foundation 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310176/
https://www.ncbi.nlm.nih.gov/pubmed/32612474
http://dx.doi.org/10.31486/toj.18.0128
_version_ 1783549321301458944
author Khan, Naseer
Reichel, Ronald
Khurshid, Ayesha
Tso, Katie
Broussard, Joan
Dass, Amrika
author_facet Khan, Naseer
Reichel, Ronald
Khurshid, Ayesha
Tso, Katie
Broussard, Joan
Dass, Amrika
author_sort Khan, Naseer
collection PubMed
description Background: Hydralazine has been known to cause multiple side effects, both localized and systemic. The literature includes case reports of systemic vasculitis caused by hydralazine. Case Report: A 79-year-old male with stage 3 chronic kidney disease attributable to hypertension and type 2 diabetes was started on hydralazine to control his hypertension. Three weeks after starting hydralazine, the patient developed nephrotic syndrome and acute kidney injury with progressively worsening proteinuria. Pathologic evaluation of the kidney tissue revealed that the patient had lupus nephritis. Immunologic markers confirmed hydralazine-induced lupus nephritis with positive antihistone antibodies. No evidence of systemic vasculitis was found. The patient's hydralazine was stopped, and the patient was treated with immunosuppressive therapy. After 7 months of immunosuppressive therapy, the patient achieved complete remission of lupus nephritis. Conclusion: Isolated renal disease induced by hydralazine as part of drug-induced lupus is uncommon. Our patient developed isolated classic lupus nephritis after hydralazine therapy with no associated systemic vasculitis. Treatment required stopping the hydralazine and initiating systemic immunosuppressive therapy to achieve complete remission.
format Online
Article
Text
id pubmed-7310176
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Academic Division of Ochsner Clinic Foundation
record_format MEDLINE/PubMed
spelling pubmed-73101762020-06-30 Hydralazine-Induced Isolated Lupus Nephritis Khan, Naseer Reichel, Ronald Khurshid, Ayesha Tso, Katie Broussard, Joan Dass, Amrika Ochsner J Case Reports and Clinical Observations Background: Hydralazine has been known to cause multiple side effects, both localized and systemic. The literature includes case reports of systemic vasculitis caused by hydralazine. Case Report: A 79-year-old male with stage 3 chronic kidney disease attributable to hypertension and type 2 diabetes was started on hydralazine to control his hypertension. Three weeks after starting hydralazine, the patient developed nephrotic syndrome and acute kidney injury with progressively worsening proteinuria. Pathologic evaluation of the kidney tissue revealed that the patient had lupus nephritis. Immunologic markers confirmed hydralazine-induced lupus nephritis with positive antihistone antibodies. No evidence of systemic vasculitis was found. The patient's hydralazine was stopped, and the patient was treated with immunosuppressive therapy. After 7 months of immunosuppressive therapy, the patient achieved complete remission of lupus nephritis. Conclusion: Isolated renal disease induced by hydralazine as part of drug-induced lupus is uncommon. Our patient developed isolated classic lupus nephritis after hydralazine therapy with no associated systemic vasculitis. Treatment required stopping the hydralazine and initiating systemic immunosuppressive therapy to achieve complete remission. Academic Division of Ochsner Clinic Foundation 2020 2020 /pmc/articles/PMC7310176/ /pubmed/32612474 http://dx.doi.org/10.31486/toj.18.0128 Text en ©2020 by the author(s); Creative Commons Attribution License (CC BY) http://creativecommons.org/licenses/by/4.0/legalcode ©2020 by the author(s); licensee Ochsner Journal, Ochsner Clinic Foundation, New Orleans, LA. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (creativecommons.org/licenses/by/4.0/legalcode) that permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
spellingShingle Case Reports and Clinical Observations
Khan, Naseer
Reichel, Ronald
Khurshid, Ayesha
Tso, Katie
Broussard, Joan
Dass, Amrika
Hydralazine-Induced Isolated Lupus Nephritis
title Hydralazine-Induced Isolated Lupus Nephritis
title_full Hydralazine-Induced Isolated Lupus Nephritis
title_fullStr Hydralazine-Induced Isolated Lupus Nephritis
title_full_unstemmed Hydralazine-Induced Isolated Lupus Nephritis
title_short Hydralazine-Induced Isolated Lupus Nephritis
title_sort hydralazine-induced isolated lupus nephritis
topic Case Reports and Clinical Observations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310176/
https://www.ncbi.nlm.nih.gov/pubmed/32612474
http://dx.doi.org/10.31486/toj.18.0128
work_keys_str_mv AT khannaseer hydralazineinducedisolatedlupusnephritis
AT reichelronald hydralazineinducedisolatedlupusnephritis
AT khurshidayesha hydralazineinducedisolatedlupusnephritis
AT tsokatie hydralazineinducedisolatedlupusnephritis
AT broussardjoan hydralazineinducedisolatedlupusnephritis
AT dassamrika hydralazineinducedisolatedlupusnephritis